Ultime notizie per Centene (NYSE:CNC) Azioni

Centene

Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.

Centene Corp

Canna Corp

CHINA NUCLEAR ENERGY TECH by CHINA NUCLEAR ENERGY TECHNOLOGY CORP LTD.

Coincheck Group NV

CANCER CAPITAL CORP by Cancer Capital Corp.

Cancer Capital Corp

CONNECTED MEDIA TECHS INC by Connected Media Technologies, Inc.

Connected Media Technologies Inc

CHUN CAN CAPITAL GROUP by Chun Can Capital Group

Chun Can Capital Group

Core Nickel Corp

CONDUIT CAPITAL LTD ORD by Conduit Capital Ltd.

Range Cancer Therapeutics ETF

CHINA CASTSON 81 FINCE by CHINA CASTSON 81 FINANCE CO.

China Teletech Holding Inc

Cluster Group Holdings Ltd Co

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 20 years by 3.56% on an annualized basis producing an average annual return of 11.55%. Currently, Centene has a market capitalization of $30.89 billion. 
Buying $1000 In CNC: If an investor had bought $1000 of CNC stock 20 years ago, it would be worth $8,812.17 today based on a price of $62.28 for CNC at the time of writing.
<h3>Centene's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744749911_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much $1000 Invested In Centene 20 Years Ago Would Be Worth Today

Baird analyst Michael Ha maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Neutral and lowers the price target from $71 to $69.

Price Target

Analyst Ratings

Baird Maintains Neutral on Centene, Lowers Price Target to $69

Guggenheim analyst Jason Cassorla initiates coverage on Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Neutral rating.

Initiation

Guggenheim Initiates Coverage On Centene with Neutral Rating

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Oppenheimer cut Autodesk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) price target from $350 to $300. Oppenheimer analyst Ken Wong maintained an Outperform rating. Autodesk shares closed at $243.62 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/ADSK/analyst-ratings">view this stock</a>.</li>
<li>B of A Securities slashed the price target for Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) from $75 to $70. B of A Securities analyst Robert Ohmes maintained an Underperform rating. Dollar Tree shares closed at $72.84 on Monday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird lowered Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) price target from $105 to $80. Baird analyst David Koning maintained an Outperform rating. Block shares closed at $50.47 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/XYZ/analyst-ratings">view this stock</a>.</li>
<li>Wells Fargo cut the price target for Ralph Lauren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) from $275 to $240. Wells Fargo analyst Ike Boruchow upgraded the stock from Equal-Weight to Overweight. Ralph Lauren shares closed at $193.17 on Monday. <a href="https://www.benzinga.com/quote/RL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup cut the price target for Knight-Swift Transportation Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) from $53 to $48. Citigroup analyst Ariel Rosa upgraded the stock from Neutral to Buy. Knight-Swift Transportation shares closed at $39.30 on Monday. <a href="https://www.benzinga.com/quote/KNX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays raised Rocket Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) price target from $10 to $14. Barclays analyst Terry Ma upgraded the stock from Underweight to Equal-Weight. Rocket Companies shares settled at $14.66 on Monday. <a href="https://www.benzinga.com/quote/RKT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan cut Levi Strauss &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) price target from $19 to $17. JP Morgan analyst Matthew Boss upgraded the stock from Neutral to Overweight. Levi Strauss shares closed at $13.50 on Monday. <a href="https://www.benzinga.com/quote/LEVI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies increased Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) price target from $53 to $64. Jefferies analyst David Windley upgraded the stock from Underperform to Hold. Centene shares closed at $61.35 on Monday.  <a href="https://www.benzinga.com/quote/CNC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity raised the price target for Rhythm Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) from $81 to $92. Canaccord Genuity analyst Whitney Ijem maintained a Buy rating. Rhythm Pharmaceuticals shares settled at $54.96 on Monday. <a href="https://www.benzinga.com/quote/RYTM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo raised Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) price target from $140 to $150. Wells Fargo analyst Ike Boruchow upgraded the stock from Equal-Weight to Overweight. Ross Stores shares closed at $127.88 on Monday. <a href="https://www.benzinga.com/quote/ROST/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying ROST stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="452" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08091839/image-39-1024x452.png" alt="" class="wp-image-861945" style="width:682px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08091839/image-39-1024x452.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08091839/image-39-300x132.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08091839/image-39-768x339.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08091839/image-39.png 1398w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/news/earnings/25/04/44678688/dow-falls-for-3rd-session-amid-trumps-tariff-threats-as-apple-tesla-decline-greed-index-remains-in-extreme-fear-zone"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44678688/dow-falls-for-3rd-session-amid-trumps-tariff-threats-as-apple-tesla-decline-greed-index-remains-in-extreme-fear-zone">Dow Falls For 3rd Session Amid Trump&#8217;s Tariff Threats As Apple, Tesla Decline: Greed Index Remains In &#8216;Extreme Fear&#8217; Zone</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

ADSK

DLTR

LEVI

ROST

RYTM

Ross Stores To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Jefferies analyst David Windley upgraded the rating for Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Underperform to Hold and raised the price target from $53 to $64. Centene shares closed at $61.35 on Monday. <a href="https://www.benzinga.com/quote/CNC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Jeremy Tonet upgraded The Southern Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>) from Underweight to Neutral and announced a $94 price target. Southern shares closed at $87.22 on Monday. <a href="https://www.benzinga.com/quote/SO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Terry Ma upgraded the rating for Rocket Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) from Underweight to Equal-Weight and increased the price target from $10 to $14. Rocket Companies shares closed at $14.66 on Monday. <a href="https://www.benzinga.com/quote/RKT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Ariel Rosa upgraded the rating for Union Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) from Neutral to Buy but lowered the price target from $260 to $244. Union Pacific shares closed at $209.97 on Monday. <a href="https://www.benzinga.com/quote/UNP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Ike Boruchow upgraded Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) from Equal-Weight to Overweight and raised the price target from $140 to $150. Ross Stores shares closed at $127.88 on Monday.  <a href="https://www.benzinga.com/quote/ROST/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CNC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="604" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08084206/image-36-1024x604.png" alt="" class="wp-image-861867" style="width:578px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08084206/image-36-1024x604.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08084206/image-36-300x177.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08084206/image-36-768x453.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08084206/image-36.png 1072w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44678688/dow-falls-for-3rd-session-amid-trumps-tariff-threats-as-apple-tesla-decline-greed-index-remains-in-extreme-fear-zone">Dow Falls For 3rd Session Amid Trump&#8217;s Tariff Threats As Apple, Tesla Decline: Greed Index Remains In &#8216;Extreme Fear&#8217; Zone</a> </li>
</ul>
Photo via Shutterstock

Upgrades

This Centene Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday

WIIM

ALHC

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Shares of health insurers are trading higher following a WSJ report indicating the Trump administration will increase Medicare Advantage rates.

Jefferies analyst David Windley upgrades Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Underperform to Hold and raises the price target from $53 to $64.

Jefferies Upgrades Centene to Hold, Raises Price Target to $64

Shares of health insurers are trading higher following a WSJ report indicating the Trump administration will increase payment rates for Medicare insurers.

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 20 years by 2.69% on an annualized basis producing an average annual return of 10.92%. Currently, Centene has a market capitalization of $29.39 billion. 
Buying $1000 In CNC: If an investor had bought $1000 of CNC stock 20 years ago, it would be worth $7,952.59 today based on a price of $59.24 for CNC at the time of writing.
<h3>Centene's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742825708_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Centene Stock In The Last 20 Years

Centene's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) short percent of float has fallen 38.22% since its last report. The company recently reported that it has 6.05 million shares sold short, which is 1.39% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.11 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Centene Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742564720_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Centene has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Centene's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Centene's peer group average for short interest as a percentage of float is 5.05%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Centene's Recent Short Interest

Contracts

Centene Subsidiary,  Meridian Health Plan of Illinois, To Continue Providing Medicare And Medicaid Services For Dually Eligible Members In Illinois

Guidance

Centene Expects To Reaffirm Its Previously Issued 2025 Adjusted EPS Guidance Of Greater Than $7.25 (Est $7.23) - Filing

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 20 years by 2.53% on an annualized basis producing an average annual return of 10.66%. Currently, Centene has a market capitalization of $29.01 billion. 
Buying $1000 In CNC: If an investor had bought $1000 of CNC stock 20 years ago, it would be worth $7,734.48 today based on a price of $58.48 for CNC at the time of writing.
<h3>Centene's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741187952_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Superior HealthPlan, A Company Of Centene To Provide $200,000 Through Annual Grant Program

Centene Plans To Reaffirm 2025 Full Year Adjusted EPS Guidance Floor Of Greater Than $7.25, Est $7.23

Shares of healthcare stocks are trading lower after President Trump signed an executive order on healthcare price transparency.

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 20 years by 1.7% on an annualized basis producing an average annual return of 10.03%. Currently, Centene has a market capitalization of $28.27 billion. 
Buying $100 In CNC: If an investor had bought $100 of CNC stock 20 years ago, it would be worth $691.43 today based on a price of $56.99 for CNC at the time of writing.
<h3>Centene's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740168011_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

Shares of health insurers are trading lower. Weakness in the sector may be in sympathy with UnitedHealth, which fell on reports of a DOJ investigation into Medicare billing practices.

Across the recent three months, 9 analysts have shared their insights on Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $78.22, with a high estimate of $93.00 and a low estimate of $52.00. A decline of 5.26% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1739563210_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Centene by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$72.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>John Stansel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$73.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$84.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$85.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$52.00</td>
<td>$68.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Centene. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Centene compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Centene's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Centene's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CNC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Centene analyst ratings.</a>
<h2>About Centene</h2>
Centene is a managed care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of September, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare Advantage (about 5%). The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program and has a military contract.
<h3>Unraveling the Financial Story of Centene</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Centene's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 10.46%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Centene's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.7% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Centene's ROE stands out, surpassing industry averages. With an impressive ROE of 2.61%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Centene's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.86%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.64.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Centene Through 9 Analysts

Wells Fargo analyst Stephen Baxter maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Overweight and lowers the price target from $76 to $72.

Comments

Centene

Notizie

Ultime notizie per Centene (NYSE:CNC) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO